Spurwing Communications
Spurwing Communications is Singapore's specialist healthcare PR agency, and it doesn't employ web developers. Since 2023 Chillybin has built its pharma clients' websites under Spurwing's banner, and Spurwing's own site in between.
Four sites delivered since 2023 for Spurwing Communications and its pharmaceutical clients, each shipped under Spurwing's banner and inside pharma's medical and regulatory review.
What we were solving
Spurwing Communications is a multi-award-winning independent communications agency in Singapore, specialising in healthcare, agribusiness and food and nutrition. Its clients include Syngenta, Kenvue and Bayer Crop Science. In July 2026 Real Chemistry, the global health innovation company, acquired Spurwing as its new Asia-Pacific hub.
Spurwing wins campaign work that needs a website. A pharma client wants a patient education hub. A biotech needs its corporate site fixed. Spurwing owns the strategy, the content and the client relationship. It doesn't employ web developers.
The web partner it needed had to meet pharma standards without being managed. Every medical statement referenced. Copy routed through the sponsor's medical and regulatory review before publication. WCAG 2.1 AA accessibility and Singapore PDPA compliance as standard. Approval cycles that run for weeks, with design and build still moving around them. And none of it visible to the end client as a second agency.
Chillybin has been that partner since August 2023.
How we tackled it
Spurwing holds the client. Chillybin handles strategy, design, build, hosting and technical SEO. On every project the job is to hit the review windows, package technical decisions so a communications consultant can present them, and never need the end client to manage us.
Spurwing's own site, for the hardest audience there is (2024)
Having seen the process on ASLAN, Spurwing commissioned its own site. The old one leaned on bright brand colours and read more consumer than corporate, which undersold communications programmes for global pharma and agribusiness companies. The audience was other communications professionals.
The design strategy phase in early 2024 set the user flow as Home, About, Sectors, Work, Contact, the order a prospect uses to evaluate an agency. We benchmarked against Mutant Communications, Sling & Stone and Sandpiper and moved the palette from vibrant to professional.
Case studies that sort themselves
The build, on WordPress with Beaver Builder, tags every case study by sector and service. The Healthcare page pulls only healthcare work and the Our Work library filters to match. Newsletter and Impact Review sign-ups carry the calls to action. Launch came with a full 301 redirect map, and Spurwing moved straight onto a Chillybin care plan. The site is still the Chillybin build today, credited in the footer, and it carried the Real Chemistry announcement in July 2026.
ASLAN Pharmaceuticals, the first project (2023 to 2024)
ASLAN Pharmaceuticals was a Singapore clinical-stage biopharma developing eblasakimab for atopic dermatitis. Its corporate site had broken links, inconsistent styles and stale product information, and investor relations ran on Drupal under another vendor. We rebuilt aslanpharma.com on WordPress with Beaver Builder, made news, publications and team profiles filtered post types, matched the design across both platforms and fed IR press releases into the corporate site. Live in 2024. ASLAN later entered liquidation and the site is no longer online.
Know More Fear Less, for Novartis Singapore (2025 to 2026)
Know More Fear Less is a Singapore breast cancer awareness campaign supported by Novartis Singapore, partnered with the Breast Cancer Foundation and Singapore Cancer Society. No infinite scroll, no clinical look, nothing that could lose someone on a bad day. We built knowmorefearless.sg on WordPress around four pages (home, education, resources, stories), every medical statement referenced, WCAG 2.1 AA and PDPA met, Novartis acknowledged as supporter without Novartis branding. The campaign team runs it without a developer; live early 2026.
#ISEEU, for Novartis Singapore (2026)
#ISEEU is Novartis Singapore's patient education site for chronic spontaneous urticaria, hives recurring for six weeks or more with no obvious trigger. We delivered iseeu.com.sg in 2026, patient-facing copy routed through Novartis medical and regulatory review. A new domain starts with nothing in search; the first technical audit scored 55/100. Changes touching no medical content shipped at once. Changes touching claims were documented as decisions for Novartis. The re-audit scored 74/100. The visibility phase runs to 31 January 2027.
What we delivered
Spurwing now has a web team it can sell as its own. Four sites have shipped under its banner since 2023. Its own site still runs on the Chillybin build and carried the news of its acquisition. Know More Fear Less and #ISEEU are live for Novartis Singapore, and the #ISEEU visibility programme runs to January 2027, past the acquisition. Each project started from trust built on the last: ASLAN before Spurwing's own site, that site before Novartis.
What we learned
Partner work has its own discipline. The client relationship belongs to Spurwing, so the measure of a good job is that the end client never notices a second agency. That restraint is the product.
Pharma is a sequencing problem. On #ISEEU the 19-point audit gain came from changes that needed no medical review. On Know More Fear Less, citations, disclaimers, PDPA and accessibility were design inputs from the strategy stage, with fixed feedback windows agreed up front. Separate what ships now from what waits for sign-off, and the governed path stops blocking everything else.
Impact & outcomes
audit issues resolved on iseeu.com.sg with zero true regressions
From the outset, the Chillybin team understood our vision and needs, patiently guiding us through every step of upgrading our website content and design.
